CNS Drugs · 2020 · 16 citations · 17 references
Life SciencesNeurologyNeuroscienceNeurodegenerationParkinson DiseaseBeta-adrenergic AgentsBeta-adrenergic Blocker UseBeta-adrenergic Receptor PharmacodynamicsBeta2-adrenergic Agonist Therapy
17
In vivo demonstration that α-synuclein oligomers are toxic
Beate Winner, Roberto Jappelli, Samir K. Maji et al. · Proceedings of the National Academy of Sciences · 2011 · 1.5K citations · Full text
β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease
Shuchi Mittal, Kjetil Bjørnevik, Adrian Flierl et al. · Science · 2017 · 437 citations · Full text
L‐type calcium channel blockers and Parkinson disease in Denmark
Beate Ritz, Shannon Rhodes, Lei Qian et al. · Annals of Neurology · 2009 · 271 citations · Full text
Use of antihypertensives and the risk of Parkinson disease
Claudia Becker, Susan S. Jick, Christoph Meier · Neurology · 2008 · 226 citations
Risk of Parkinson Disease Onset in Patients With Diabetes
Yu Sun, Ya‐Hui Chang, Hua-Fen Chen et al. · Diabetes Care · 2012 · 183 citations · Full text
Medicine, Endocrinology, Neurology +17